ViroGates Announces its third clinical routine customer
Company announcement no. 5-2019
Birkerød, 25 April 2019
ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in hospitals, today announces that Amager Hospital, Denmark has entered an agreement with ViroGates as paying customer for the use of suPARnostic® TurbiLatex in clinical routine practice for the triage and severity assessment of acute clinical patients. The hospital is run by the Capital Region and treats approximately 50,000 patients annually of which approximately 16,000 are admitted for hospitalisation. The hospital is operating its own acute clinical department, while management of the hospital is jointly operated with Hvidovre Hospital.
CEO Jakob Knudsen, says in a comment: ”We are very pleased to announce another clinical customer that starts using suPARnostic® to help in the risk assessment of acute clinical patients. We are furthermore happy to see that Amager Hospital will be the first customer to run the newly developed suPARnostic® TurbiLatex product at its clinical biochemistry laboratory on the Roche Diagnostics cobas instrument. We look forward to work with other hospitals to curb the effects of the increasing number of patients with co-morbidities that are so difficult to risk assess. With the availability of suPARnostic®, risk assessment will be improved, allowing better clinical decisions, better patient care and optimisation of hospital resources.”
Professor, Dm.Sc, MD, Ove Andersen comments: “Over the last years, suPAR has shown to be a strong marker of risk in acute medical patients independent of the clinical signs used to triage patients. The addition of suPAR improves risk prediction of both low- and high-risk acute medical patients and suPAR can therefore corroborate the decision of admission or discharge. We are pleased that Amager Hospital will now have access to the knowledge provided by suPAR.
For further information contact:
CEO Jakob Knudsen
Tel. (+45) 2113 1336, Email:
ViroGates A/S
CVR-nr. 25734033
Blokken 45, DK-340 Birkerød
Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email:
About ViroGates
ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 550 clinical trials and studies which included more than 350,000 blood samples.
Attachment
